Faeth Therapeutics, Inc. 8-K

What Happened

• Faeth Therapeutics filed a Form 8‑K on June 18, 2026 disclosing an at‑the‑market (ATM) sales agreement with TD Securities (USA) LLC that allows the company to offer and sell up to $150,000,000 of common stock under a Form S‑3 registration statement. The agreement permits sales from time to time at the company's direction; TD Securities will use commercially reasonable efforts to sell shares and may earn a commission up to 3.0%.
• The company also reported that certain Series B non‑voting convertible preferred shares automatically converted into 24,435,594 shares of common stock, bringing total common shares outstanding to 25,778,754 as of June 15, 2026.

Key Details

• ATM program size: up to $150,000,000 of common stock (offering under Form S‑3 and related prospectus filed June 18, 2026).
• Agent: TD Securities (USA) LLC; commission: up to 3.0% of gross sales.
• Sales may be executed as "at‑the‑market offerings" under Rule 415(a)(4). The company has no obligation to sell and may suspend or terminate the program at any time.
• Preferred conversion: 24,435,594 common shares issued from conversion; total common outstanding: 25,778,754 (as of June 15, 2026).

Why It Matters

• The ATM gives Faeth a flexible, on‑demand way to raise capital by selling shares into the market; this can support operations, R&D or other corporate needs without a single large offering.
• Issuing new shares through the ATM and the recent large preferred‑to‑common conversion increase the company’s outstanding common stock and therefore can be dilutive to existing shareholders when shares are sold.
• Investors should note there is no certainty or schedule for sales under the ATM, and selling through an agent incurs up to a 3% commission which reduces net proceeds.